Profilin as a Novel Target for Vascular Normalization in Renal Cancer

Profilin 作为肾癌血管正常化的新靶点

• 批准号: 10686091
• 负责人: David Martin Gau
• 金额: $ 12.6万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10686091
• 关键词: Actin-Binding Protein; Actins; Affect; Agonist; Angiogenesis Inhibitors; Attenuated; Automobile Driving; Autophagocytosis; Bioenergetics; Biological Process; Biology; Blood Vessels; Cell Proliferation; Cell secretion; Cessation of life; Clear cell renal cell carcinoma; Clinical; Cytoskeleton; Data; Deterioration; Disease; Endothelium; Gene Expression; Genetic; Glycolysis; Goals; Growth; Human; Hypoxia; Immunologics; In Vitro; Kidney; Link; Malignant Epithelial Cell; Mediating; Mediator; Mentors; Microvascular Permeability; Mitochondria; Molecular Target; Neoplasms in Vascular Tissue; Outcome; Paracrine Communication; Pathologic; Patients; Perfusion; Pharmaceutical Preparations; Phenotype; Physiological; Play; Polymers; Process; Refractory Disease; Regulation; Renal Cell Carcinoma; Renal carcinoma; Resistance; Resistance development; Respiration; Rest; Retina; Role; Signal Transduction; Testing; Therapeutic; Training; Tumor Cell Migration; Tumor Promotion; Vaccines; Vascular Endothelial Cell; Vascular Endothelial Growth Factors; Vascularization; advanced disease; angiogenesis; antagonist; cell motility; extracellular; improved; in vivo; neoplastic cell; normoxia; novel; overexpression; paracrine; patient prognosis; polymerization; profilin; receptor; small molecule; small molecule inhibitor; targeted treatment; therapeutic target; therapy outcome; therapy resistant; treatment strategy; tumor; tumor microenvironment; tumor progression; tumor-immune system interactions; tumorigenic; ultrasound; virtual

Project Summary Abstract Renal cell carcinoma (RCC) is estimated to result in 76,080 new cases and 13,780 deaths in 2021. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC (>75% of RCC patients) and is characterized by a high vascularized tumor microenvironment (TME). Anti- angiogenic and vascular normalization (VN) inducing therapies are initially effective, almost all patients develop resistance to these therapies. Therefore, there is a need to identify alternative fundamental therapies for ccRCC. Our lab and others have demonstrated that actin cytoskeleton plays a key role in regulation of vascular endothelial cell (VEC) in angiogenesis and barrier function. Furthermore, it has been demonstrated that Profilin1 (Pfn1) is an important regulator of actin-driven processes such as cell migration and proliferation (including in VEC, affecting angiogenic potential). Pfn1 is also overexpressed in human ccRCC and higher expression of Pfn1 has been linked to poor clinical outcome and advanced disease features. The goal of this study is to further demonstrate Pfn1’s fundamental role in regulation of progression of ccRCC through modulation of tumor- promoted vascularization and that Pfn1 serves as a therapeutic target for RCC. Our preliminary data demonstrates that overexpressed Pfn1 is primarily found in tumor-associated VEC (TAEC). We further demonstrate that loss of Pfn1 by genetic deletion in vivo or inhibition of Pfn1 by small molecule inhibitor reduces aberrant vascularization in various pathological settings (including retina and kidney) and attenuates RCC progression in vivo. Aim 1 of this proposal seeks to test a postulate that endothelial Pfn1 promotes a pro- tumorigenic TME driving tumor progression in ccRCC and can be diminished by tumor-localized delivery of novel small molecule antagonist of Pfn1-actin interaction. Aim 2 of this proposal will test a postulate that Pfn1 regulates the intrinsic angiogenic capability of VEC through augmenting mitochondrial function. Aim 3 tests a postulate that VEC-secreted Pfn1 acts as a paracrine signaling mediator to promote ccRCC aggressiveness. Aims 1 and 2 will mostly be performed in the K99 mentored stage, during which I will continue my training in contrast-enabled ultrasound, immuno-, and mitochondrial biology. These trainings will be pivotal in my transition to independence in the R00 stage where Aim 3 and the rest of Aim 2 will be executed.

项目摘要 据估计，2021年肾细胞癌（RCC）将导致76，080例新发病例和13，780例死亡。透明细胞 肾细胞癌（ccRCC）是RCC的最常见亚型（>75%的RCC患者）， 其特征在于高度血管化的肿瘤微环境（TME）。抗血管生成和血管 正常化（VN）诱导疗法最初是有效的，几乎所有患者都对这些疗法产生耐药性。 治疗因此，需要确定ccRCC的替代基础疗法。我们的实验室和 其他人已经证明肌动蛋白细胞骨架在调节血管内皮细胞中起关键作用， (VEC)血管生成和屏障功能。此外，已经证明Profilin 1（Pfn 1）是一种 肌动蛋白驱动过程如细胞迁移和增殖（包括在VEC中， 影响血管生成潜力）。Pfn 1在人ccRCC中也过表达，并且Pfn 1表达更高 与不良临床结果和晚期疾病特征有关。本研究的目的是进一步 证明Pfn 1通过调节肿瘤- 促进血管形成，Pfn 1可作为RCC的治疗靶点。我们的初步数据 表明Pfn 1的过度表达主要存在于肿瘤相关VEC（TAEC）中。我们进一步 证明了通过体内遗传缺失或通过小分子抑制剂抑制Pfn 1而导致Pfn 1损失 减少各种病理环境（包括视网膜和肾脏）中的异常血管形成， 体内RCC进展。该提案的目的1试图测试内皮Pfn 1促进促血小板生成素的假设。 致瘤性TME驱动ccRCC中的肿瘤进展，并且可以通过肿瘤局部递送 Pfn 1-肌动蛋白相互作用的新型小分子拮抗剂。本提案的目标2将检验一个假设，即Pfn 1 通过增强线粒体功能调节VEC的内在血管生成能力。目标3测试a 假设VEC分泌的Pfn 1作为旁分泌信号介质促进ccRCC的侵袭性。 目标1和2将主要在K99指导阶段执行，在此期间，我将继续我的培训， 对比超声、免疫和线粒体生物学。这些培训将是关键在我的 在R 00阶段过渡到独立，目标3和目标2的其余部分将被执行。